Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Part 1 and Part 2: Resident or facility staff in a skilled nursing or assisted living facility with at least one confirmed case of SARS-CoV-2 detection less than or equal to (≤)7 days prior to randomization~* Are men or non-pregnant women who agree to contraceptive requirements~* Agree to the collection of nasal, mid-turbinate, oropharyngeal, and nasopharyngeal swabs, and venous blood as specified in the schedule of activities~* Have venous access sufficient to allow intravenous infusions and blood sampling~* The participant or legally authorized representative give signed informed consent~* Part 3 only: Resident or staff in a skilled nursing or assisted living facility who satisfy at least one of the following at the time of screening~  * Are greater than or equal to (≥) 65 years of age~ * Have a body mass index (BMI) ≥ 35~ * Have chronic kidney disease~ * Have type 1 or type 2 diabetes~ * Have immunosuppressive disease~ * Are currently receiving immunosuppressive treatment, or~ * Are ≥ 55 years of age AND have~    * cardiovascular disease, OR~   * hypertension, OR~   * chronic obstructive pulmonary disease or other chronic respiratory disease~* Positive SARS-CoV-2 test and infusion within 10 days of symptom onset, OR positive SARS-CoV-2 test and infusion within 10 days of testing if asymptomatic~Exclusion Criteria:~* Parts 1 and 2:~  * Recovered from confirmed COVID-19 disease or asymptomatic infection~ * Prior history of a positive SARS-CoV-2 serology test~ * History of convalescent COVID-19 plasma treatment~ * Participation in a previous SARS-CoV-2 vaccine trial or received an approved SARS-CoV-2 vaccine~ * Previous receipt of SAR-CoV-2-specific monoclonal antibodies~* Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bamlanivimab (Part 1) (Type: EXPERIMENTAL): Participants received single Intravenous (IV) infusion of 4200 milligrams (mg) bamlanivimab.
- Placebo (Part 1) (Type: PLACEBO_COMPARATOR): Participants received single IV infusion of Placebo.
- Bamlanivimab (Part 2-Prevention) (Type: EXPERIMENTAL): Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
- Bamlanivimab + Etesevimab (Part 2-Prevention) (Type: EXPERIMENTAL): Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
- Placebo Comparator: Placebo (Part 2-Prevention) (Type: PLACEBO_COMPARATOR): Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
- Bamlanivimab (Part 2 - Treatment) (Type: EXPERIMENTAL): Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
- Bamlanivimab + Etesevimab (Part 2- Treatment) (Type: EXPERIMENTAL): Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
- Bamlanivimab (Part 3) (Type: EXPERIMENTAL): Part 3 of the study is exploratory, conducted to study exploratory objectives and is not reported in this record.~\[Participants received single IV infusion of 700 mg bamlanivimab.\]
- Bamlanivimab + Etesevimab (Part 3) (Type: EXPERIMENTAL): Part 3 of the study is exploratory, conducted to study exploratory objectives and is not reported in this record.~\[Participants received single IV infusion of 700 mg bamlanivimab given with 1400 mg etesevimab.\]

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete